Skip to main content
Equibles
ATNM logo

ATNM · Actinium Pharmaceuticals, Inc. · Metrics

Track ATNM — free

Use ATNM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATNM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.59 +0.00 (+0.00%) At close · Nov 12
Rebalance outlook locked
Market Cap
$49.99M
Shares
31.44M
Volume · Nov 12 348.12K Avg daily vol (3M) 190.03K

ATNM metrics

71 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.59
Market cap
$49.99M

Price action

23 metrics
Price change (1W)
+12.8%
Price change (30D)
+59.1%
Price change (3M)
+93.7%
Price change (6M)
+23.3%
Price change (YTD)
+16.9%
Price change (1Y)
+21.4%
Trailing year
Price change (5Y)
-79.7%
52-week high
$1.69
52-week low
$0.75
Change from 52-week high
-5.9%
Change from 52-week low
+112.3%
Annualized volatility
74.2%
Annualized volatility (3M)
95.6%
Implied volatility (30D)
363.4%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
63.1
Price vs SMA 50
+26.2%
Price vs SMA 200
+41.2%
Avg volume (3M)
188,379
Relative volume
0.6
Average dollar volume
$237,437

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
31.44M

Valuation

12 metrics
P / E (TTM)
4.5
Trailing earnings · reciprocal yield 22.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
1.4×
reciprocal yield 72.3%
EV / EBIT
1.4×
reciprocal yield 70.7%
P / sales
—
P / book
1.6
reciprocal yield 60.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
22.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-40,274.4%
Trailing 12 months
Net margin
-37,652.2%
Gross profit (TTM)
$0
Operating profit (TTM)
$9.56M
Net income (TTM)
$11.31M
Trailing 12 months
Diluted EPS (TTM)
$0.35
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$0.30
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$0.36
Operating cash flow per diluted share (TTM)
$-0.73
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.58
Stock compensation per diluted share (TTM)
$0.01
Book value per share
$0.25

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.7%
Year over year · more shares
Revenue CAGR (3Y)
-55.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
37.3%
Return on assets
28.2%
Debt / equity
0.0
Current ratio
4.1
EBITDA (TTM)
$9.78M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
-3.7
Return on invested capital
—
Trailing 12 months
Net cash
$36.47M
Latest balance sheet
Cash & equivalents
$36.47M
Total assets
$40.16M
Total debt
$5,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$22.66M
Capital expenditures (TTM)
—
R&D (TTM)
$18.12M
SG&A (TTM)
—
Stock compensation (TTM)
$248,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
47
13F filer change QoQ
-7
Institutional ownership
16.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.2%
Private-fund adviser ownership
4.0%
Active holders' share change QoQ
-18.0%
Holder tenure
6.9
Price vs estimated holder cost
-55.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.1%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 1.7 days to cover
Days to cover
1.7d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1388320 CUSIP 00507W206 13F (30d) 33 filings 23 filers Visit website Investor relations